N/A N=473 Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Behcet's Disease
Primary: Number of Participants With Adverse Drug Reactions — 47; 5; 6; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
Intestinal Behçet's Disease
Primary: Number of Participants With Marked Improvement at Week 24 — 9 participants
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Phase 3 N=207 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
Behçet's Syndrome
Primary: Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) — 222.14; 129.54 Ulcers*days — p=<0.0001
Phase 2 N=84 Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
Behcet Syndrome · Behcet Disease · Mucocutaneous Ulceration
Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Phase 2 N=6 Anakinra for Behcet s Disease
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants
Phase 2 N=111 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
Behcet Syndrome
Primary: Number of Oral Ulcers at Day 85 — 2.0; 0.4 ulcers/participants — p=<0.0001
Phase 3 N=18 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Behcet's Disease · Behcet Syndrome · Neuro-Behcet's Disease
Primary: Percentage of Participants With Complete Response at Week 30 — 54.5; 0; 100; 100 percentage of Complete Responders
Phase 3 N=118 Phase III Study in Refractory Behcet's Disease
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
Phase 2 N=8 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Behcet Disease
Primary: Number of Participants With Attacks — 0 Participants
Phase 2 N=22 Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Phase 3 N=112 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Crohn's Disease
Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
N/A N=15 Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=15 The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
N/A N=191 Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
Crohn Disease
Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants
N/A N=98 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease
Crohn's Disease
Primary: Diagnostic Yield in Suspected Crohn's Patients (CE Prior to IC vs. IC and SBFT) — 97.3; 57.3 percentage of yield — p=<0.0001
Phase 2 N=34 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
Inflammatory Bowel Disease · Ulcerative Colitis · Crohn's Disease
Primary: Patient Clinical Experience — 1.2; 1.3 units on a scale — p=<0.05
Phase 3 N=89 Mucosal Healing Study in Crohn's Disease (CD)
Crohn's Disease
Primary: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments — -6.47 score on a scale
N/A N=407 Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil
Inflammatory Bowel Disease
Primary: Percentage of Participants With Active Crohn's Disease (CD) at Day 1 — 16.52; 25.97 percentage of participants
Phase 4 N=55 Triple Combination Therapy in High Risk Crohn's Disease (CD)
Crohn Disease
Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Phase 2 N=30 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants